Other studies show that blocking the production or inhibiting the effects of Angiotensin II (Ang II) could block or delay cardiac remodeling, reducing mortality and morbidity, as demonstrated experimentally by the exogenous addition of the vasodilator Ang (1–7), which improved cardiac function after myocardial infarction [49,53]. The gene discussed is AGT; the disease is myocardial infarction.